(2R)-3-(4-{[3-(3,4-dichlorophenyl)isoxazol-5-yl]methyl}piperazinyl)-1-(2-methylbenzothiazol-5-yloxy)propan-2-ol | 1055972-85-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: (2R)-3-(4-{[3-(3,4-dichlorophenyl)isoxazol-5-yl]methyl}piperazinyl)-1-(2-methylbenzothiazol-5-yloxy)propan-2-ol
• 英文别名: (2R)-1-[4-[[3-(3,4-dichlorophenyl)-1,2-oxazol-5-yl]methyl]piperazin-1-yl]-3-[(2-methyl-1,3-benzothiazol-5-yl)oxy]propan-2-ol
• CAS: 1055972-85-4
• 化学式: C₂₅H₂₆Cl₂N₄O₃S
• 分子量: 533.478
• InChiKey: GBDCOMBDTHQXQJ-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• SUBSTITUTED HETEROCYCLIC COMPOUNDS
  申请人：CV Therapeutics Inc.

  公开号：EP1583760A2

  公开（公告）日：2005-10-12
• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUE SUBSTITUES
  申请人：CV THERAPEUTICS INC

  公开号：WO2004067506A2

  公开（公告）日：2004-08-12

  Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.